Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870336 | 0.93 | PIK3CD (0.49) | PIK3CDKDM4EGRM2PER2CRY2 | |
| SCHEMBL8391424 | 0.87 | PIK3CD (0.46) | PIK3CDKDM4EGRM2PER2CRY2 | |
| SCHEMBL10337440 | 0.80 | KDM4E (0.42) | PIK3CDKDM4EGRM2PER2CRY2 | |
| SCHEMBL8157458 | 0.78 | PIK3CD (0.41) | PIK3CDKDM4E | |
| SCHEMBL10337812 | 0.76 | KDM4E (0.39) | PIK3CDKDM4E | |
| SCHEMBL29954446 | 0.75 | KDM4E (0.46) | PIK3CDKDM4EGRM2PER2CRY2 | |
| SCHEMBL8158607 | 0.75 | MGLL (0.43) | PIK3CD | |
| SCHEMBL4870239 | 0.75 | L3MBTL1 (0.44) | PIK3CD | |
| SCHEMBL8156906 | 0.73 | PIK3CD (0.45) | PIK3CDKDM4EGRM2PER2CRY2 | |
| SCHEMBL20733171 | 0.73 | PIK3CD (0.51) | PIK3CDKDM4EGRM2PER2CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361648-B2 | Heterocyclylakylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2008-04-22 | — | — | US | disclosed |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | ROCHE PALO ALTO LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094778-B2 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1289965-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-6818645-B2 | 2-AMINO-TRIHYDROINDOLE OR TETRAHYDRONAPTHALENE-2-YL DERIVATIVES, USEFUL FOR DISEASE STATE ASSOCIATED WITH SMOOTH MUSCLE DISORDERS, SUCH AS GASTROINTESTINAL AND UROGENITAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-16 | — | — | US | disclosed |
| EP-1289964-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | DVORAK CHARLES ALOIS (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040034018-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | WEIKERT ROBERT JAMES (US) | 2004-02-19 | — | — | US | disclosed |
| US-6667301-B2 | Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders | SYNTEX (U.S.A.) LLC | 2003-12-23 | — | — | US | disclosed |
| US-6645958-B2 | Oxazepine derivatives; urogenital, gastrointestinal, and respiratory system disorders; antiasthmatic and antiallergen agents | SYNTEX (U.S.A.) LLC | 2003-11-11 | — | — | US | disclosed |
| US-20030109524-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | WEIKERT ROBERT JAMES (US) | 2003-06-12 | — | — | US | disclosed |
| US-6500822-B2 | MUSCULAR DISORDERS, GASTROINTESTINAL DISORDERS, RESPIRATORY SYSTEM DISORDERS | SYNTEX (U.S.A.) LLC | 2002-12-31 | — | — | US | disclosed |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
| US-20020004494-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004494-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM4 | PIK3CD 3912/4885KDM4E 1744/4885GRM2 109/4885 |
| US-20030109524-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM4 | PIK3CD 3912/4885KDM4E 1744/4885GRM2 109/4885 |
| US-20040034018-A1 | Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM4 | PIK3CD 3912/4885KDM4E 1744/4885GRM2 109/4885 |
| US-20060287293-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM3 | PIK3CD 3258/4885KDM4E 2261/4885GRM2 198/4885 |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | PIK3CD 3151/4885KDM4E 2601/4885GRM2 168/4885 |
| US-20040087581-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | PIK3CD 3151/4885KDM4E 2601/4885GRM2 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.